Loading patent…
AssigneeStemgen S.P.A.
InventorsAngelo Luigi Vescovi, Brent Allen Reynolds
Estimating the term…
The present disclosure includes methods and compositions for the treatment or prevention of diseases and disorders characterized by excessive or misregulated cellular proliferations, including methods for the treatment of tumors. The methods involve the use of pharmaceutical compositions comprising at least one agent selected from the group consisting of a LIF preparation, a BMP preparation, a BMPR signalling activator, and a LIFR signalling activator. The disclosure also includes LIF preparations, BMP preparations, BMPR signalling activator, and LIFR signalling activators, and methods for the identification of LIF preparations, BMP preparations, BMPR signalling activator, and LIFR signalling activators. The disclosure also includes pharmaceutical compositions comprising at least one agent selected from the group consisting of a LIF preparation, a BMP preparation, a BMPR signalling activator, and a LIFR signalling activator.
Use of a BMP preparation in the manufacture of a medicament for the treatment of a disease characterized by excessive or misregulated cellular proliferation.
Use of a LIF preparation in the manufacture of a medicament for the treatment of a disease characterized by excessive or misregulated cellular proliferation.
A method of treating a disease in a subject characterized by excessive or misregulated cellular proliferation, the method comprising administering to said subject a pharmaceutical composition comprising at least one agent selected from the group consisting of a Bone Morphogenetic Protein (BMP) preparation, a Leukemia Inhibitory Factor (LIF) preparation, a Leukemia Inhibitory Factor Receptor (LIFR) signalling activator and a Bone Morphogenetic Protein Receptor (BMPR) signalling activator.
A method of increasing BMP Receptor (BMPR) mediated signalling in a tumor stem cell or a tumor progenitor cell comprising administering a BMP preparation to said tumor stem cell or said tumor progenitor cell.
A method of increasing LIF Receptor (LIFR) mediated signalling in a tumor stem cell or a tumor progenitor cell comprising administering a LIF preparation to said tumor stem cell or said tumor progenitor cell.
A method for decreasing the number of tumor stem cells and/or tumor progenitor cells in a tumor comprising contacting the tumor with a BMP preparation.
A method for decreasing the number of tumor stem cells and/or tumor progenitor cells in a tumor comprising contacting the tumor with a BMPR signalling activator.
A method for decreasing the number of tumor stem cells and/or tumor progenitor cells in a tumor comprising contacting the tumor with a LIF preparation.
A method for decreasing the number of tumor stem cells and/or tumor progenitor cells in a tumor comprising contacting the tumor with a LIFR signalling activator.
A method for reducing the growth of a tumor comprising activating BMPR-mediated signalling in said tumor.
A method for reducing the growth of a tumor comprising activating LIFR-mediated signalling in said tumor.
A pharmaceutical composition comprising a BMP Receptor (BMPR) signalling activator.
A pharmaceutical composition comprising a LIFR Receptor (LIFR) signalling activator.
A BMP Receptor (BMPR) signalling activator.
A LIFR Receptor (LIFR) signalling activator.
A pharmaceutical composition comprising a BMP preparation associated with at least one polymeric wafer or at least one polymeric bead.
A pharmaceutical composition comprising a LIFR signalling activator and a BMPR signalling activator.
A method for reducing the likelihood that a tumor stem cell or tumor progenitor cell undergoes a symmetrical division, the method comprising contacting the tumor stem cell or tumor progenitor cell with at least one agent selected from the group consisting of a LIF preparation, a BMP preparation, a BMPR signalling activator, and a LIFR signalling activator.
A method for identifying a BMPR signalling activator from a candidate mixture of molecules, the method comprising the steps of:
A method of treating a glioblastoma multiforme in a human patient comprising at least partially resecting said glioblastoma multiforme to form a resection cavity and releasing a BMP-4 preparation into said resection cavity.
A method of treating a tumor which comprises tumor stem cells, the method comprising contacting said tumor stem cells with an agent that induces differentiation of said tumor stem cells.
Dependencies are inferred from the claim text.